EGFR and non-small cell lung carcinoma: For instance, mutations in erbB1 (the protein product of which is EGFR) are known to be driver mutations in a subset of patients with NSCLC; these mutations are much more prevalent in Asian patients (30%–40%) than in Western patients (15%), and highly effective TKIs targeting mutant EGFR are in widespread clinical use.